Quick Answer
Alto Neuroscience, Inc. reported Net Income of -$63.24 million for fiscal year 2025.
Alto Neuroscience, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$63.24M -2.9% |
-$61.43M -69.2% |
-$36.30M | — |
| Diluted EPS | -$2.19 +12.4% |
-$2.50 +74.3% |
-$9.73 | — |
| Total Assets | $184.69M +4.0% |
$177.54M +104.9% |
$86.63M | — |
| Cash and Equivalents | $176.48M +4.9% |
$168.23M +103.8% |
$82.55M | — |
| Long-Term Debt | $16.17M +57.7% |
$10.25M +4.0% |
$9.86M | — |
| Stockholders Equity | $151.14M -0.2% |
$151.46M +311.3% |
-$71.67M -86.6% |
-$38.41M |
| R&D Expense | $45.62M -2.9% |
$47.00M +55.1% |
$30.29M | — |
| Operating Income | -$66.36M +3.3% |
-$68.61M -81.5% |
-$37.81M | — |
| Shares Outstanding | 31.92M +18.3% |
26.99M +604.2% |
3.83M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$14.18M | +15.5% | +19.9% |
| Diluted EPS | September 30, 2025 | -$0.52 | +16.1% | +20.0% |
| Total Assets | September 30, 2025 | $147.01M | -23.3% | -6.9% |
| Cash and Equivalents | September 30, 2025 | $137.82M | -24.2% | -6.6% |
| Long-Term Debt | September 30, 2025 | $20.31M | +206.5% | +1.0% |
| Stockholders Equity | September 30, 2025 | $111.56M | -32.4% | -9.6% |
| R&D Expense | September 30, 2025 | $10.53M | -19.4% | -19.8% |
| Operating Income | September 30, 2025 | -$14.95M | +20.8% | +20.0% |
| Shares Outstanding | September 30, 2025 | 27.17M | +0.7% | +0.4% |
- Alto Neuroscience, Inc. reported Net Income of -$63.24 million for fiscal year 2025.
- Alto Neuroscience, Inc. showed a decrease of -2.9% in Net Income compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported Diluted EPS of $2.19 per share (loss) for fiscal year 2025.
- Alto Neuroscience, Inc. showed an increase of +12.4% in Diluted EPS compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported Total Assets of $184.69 million for fiscal year 2025.
- Alto Neuroscience, Inc. showed an increase of +4.0% in Total Assets compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported Cash and Equivalents of $176.48 million for fiscal year 2025.
- Alto Neuroscience, Inc. showed an increase of +4.9% in Cash and Equivalents compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported Long-Term Debt of $16.17 million for fiscal year 2025.
- Alto Neuroscience, Inc. showed an increase of +57.7% in Long-Term Debt compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported Stockholders Equity of $151.14 million for fiscal year 2025.
- Alto Neuroscience, Inc. showed a decrease of -0.2% in Stockholders Equity compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported R&D Expense of $45.62 million for fiscal year 2025.
- Alto Neuroscience, Inc. showed a decrease of -2.9% in R&D Expense compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported Operating Income of -$66.36 million for fiscal year 2025.
- Alto Neuroscience, Inc. showed an increase of +3.3% in Operating Income compared to the prior fiscal year.
- Alto Neuroscience, Inc. reported Shares Outstanding of 31.92 million shares for fiscal year 2025.
- Alto Neuroscience, Inc. showed an increase of +18.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: